The role of PAQR3 gene promoter hypermethylation in breast cancer and prognosis

Chen,Jinpeng; Wang,Feiran; Xu,Junfei; He,Zhixian; Lu,Yuhua; Wang,Zhiwei

doi:10.3892/or.2016.4951

The role of PAQR3 gene promoter hypermethylation in breast cancer and prognosis

Authors:
- Jinpeng Chen
- Feiran Wang
- Junfei Xu
- Zhixian He
- Yuhua Lu
- Zhiwei Wang
View Affiliations

Affiliations: Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: July 19, 2016 https://doi.org/10.3892/or.2016.4951
Pages: 1612-1618

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

PAQR3 is a tumor suppressor in breast cancer and its expression regulation mechanism has not been well elucidated. In this study, we found that PAQR3 expression was downregulated in breast cancer tissues, and the downregulation of PAQR3 expression was found to be significantly associated with aberrant methylation of the gene promoter. Methylation‑specific PCR showed that hypermethylation of the PAQR3 gene was observed in 71.8% of the breast cancers, whereas it was found in only 28.2% of the corresponding non‑tumor tissues. Moreover, we found that the PAQR3 promoter methylation status was related to lymph node metastasis (P=0.01). In addition, overexpression of PAQR3 inhibited breast cancer cell invasion and growth. Furthermore, PAQR3 expression was restored in MCF‑7 cells after treatment with the demethylating agent, 5-aza-2'-deoxycytidine, and the effect of demethylation induced invasion and proliferation suppression of MCF‑7 cells. Collectively, our results suggested that the aberrant methylation of PAQR3 underlies its downregulation in breast cancer and our data indicated that epigenetic silencing of PAQR3 gene expression by promoter hypermethylation may play an important role in breast cancer.

View Figures

View References

1	Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, Sledge G and Visco FM: Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer. 7:309–315. 2007. View Article : Google Scholar : PubMed/NCBI
2	Liu Y, Li H, Feng J, Cui X, Huang W, Li Y, Su F, Liu Q, Zhu J, Lv X, et al: Lin28 induces epithelial-to-mesenchymal transition and stemness via downregulation of let-7a in breast cancer cells. PLoS One. 8:e830832013. View Article : Google Scholar : PubMed/NCBI
3	Dworkin AM, Huang TH and Toland AE: Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 19:165–171. 2009. View Article : Google Scholar : PubMed/NCBI
4	Feng L, Xie X, Ding Q, Luo X, He J, Fan F, Liu W, Wang Z and Chen Y: Spatial regulation of Raf kinase signaling by RKTG. Proc Natl Acad Sci USA. 104:14348–14353. 2007. View Article : Google Scholar : PubMed/NCBI
5	Luo X, Feng L, Jiang X, Xiao F, Wang Z, Feng GS and Chen Y: Characterization of the topology and functional domains of RKTG. Biochem J. 414:399–406. 2008. View Article : Google Scholar : PubMed/NCBI
6	Xie X, Zhang Y, Jiang Y, Liu W, Ma H, Wang Z and Chen Y: Suppressive function of RKTG on chemical carcinogen-induced skin carcinogenesis in mouse. Carcinogenesis. 29:1632–1638. 2008. View Article : Google Scholar : PubMed/NCBI
7	Zhang Y, Jiang X, Qin X, Ye D, Yi Z, Liu M, Bai OW, Xie X, Wang Z, et al: RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is down-regulated in clear-cell renal cell carcinoma. Oncogene. 29:5404–5415. 2010. View Article : Google Scholar : PubMed/NCBI
8	Fan F, Feng L, He J, Wang X, Jiang X, Zhang Y, Wang Z and Chen Y: RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells. Carcinogenesis. 29:1157–1163. 2008. View Article : Google Scholar : PubMed/NCBI
9	Wang X, Li X, Fan F, Jiao S, Wang L, Zhu L, Pan Y, Wu G, Ling ZQ, Fang J, et al: PAQR3 plays a suppressive role in the tumorigenesis of colorectal cancers. Carcinogenesis. 33:2228–2235. 2012. View Article : Google Scholar : PubMed/NCBI
10	Ling ZQ, Guo W, Lu XX, Zhu X, Hong LL, Wang Z, Wang Z and Chen Y: A Golgi-specific protein PAQR3 is closely associated with the progression, metastasis and prognosis of human gastric cancers. Ann Oncol. 25:1363–1372. 2014. View Article : Google Scholar : PubMed/NCBI
11	Ma Z, Wang Y, Piao T, Li Z, Zhang H, Liu Z and Liu J: The tumor suppressor role of PAQR3 in osteosarcoma. Tumour Biol. 36:3319–3324. 2015. View Article : Google Scholar
12	Tang YT, Hu T, Arterburn M, Boyle B, Bright JM, Emtage PC and Funk WD: PAQR proteins: A novel membrane receptor family defined by an ancient 7-transmembrane pass motif. J Mol Evol. 61:372–380. 2005. View Article : Google Scholar : PubMed/NCBI
13	Wang L, Wang X, Li Z, Xia T, Zhu L, Liu B, Zhang Y, Xiao F, Pan Y, Liu Y, et al: PAQR3 has modulatory roles in obesity, energy metabolism, and leptin signaling. Endocrinology. 154:4525–4535. 2013. View Article : Google Scholar : PubMed/NCBI
14	Jiang Y, Xie X, Li Z, Wang Z, Zhang Y, Ling ZQ, Pan Y, Wang Z and Chen Y: Functional cooperation of RKTG with p53 in tumorigenesis and epithelial-mesenchymal transition. Cancer Res. 71:2959–2968. 2011. View Article : Google Scholar : PubMed/NCBI
15	Yu X, Li Z, Chan MT and Wu WK: PAQR3: A novel tumor suppressor gene. Am J Cancer Res. 5:2562–2568. 2015.PubMed/NCBI
16	Wang X, Wang L, Zhu L, Pan Y, Xiao F, Liu W, Wang Z, Guo F, Liu Y, Thomas WG, et al: PAQR3 modulates insulin signaling by shunting phosphoinositide 3-kinase p110α to the Golgi apparatus. Diabetes. 62:444–456. 2013. View Article : Google Scholar :
17	Liu C, Zhang Y, Hou Y, Shen L, Li Y, Guo W, Xu D, Liu G, Zhao Z, Man K, et al: PAQR3 modulates H3K4 trimethylation by spatial modulation of the regulatory subunits of COMPASS-like complexes in mammalian cells. Biochem J. 467:415–424. 2015. View Article : Google Scholar : PubMed/NCBI
18	Jones PA and Baylin SB: The epigenomics of cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
19	Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 8:286–298. 2007. View Article : Google Scholar : PubMed/NCBI
20	Wu Q, Zhuang K and Li H: PAQR3 plays a suppressive role in laryngeal squamous cell carcinoma. Tumour Biol. 37:561–565. 2016. View Article : Google Scholar
21	Wu HG, Zhang WJ, Ding Q, Peng G, Zou ZW, Liu T, Cao RB, Fei SJ, Li PC, Yang KY, et al: Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma. Oncol Rep. 32:2687–2695. 2014.PubMed/NCBI
22	Li Z, Ling Z-Q, Guo W, Lu XX, Pan Y, Wang Z and Chen Y: PAQR3 expression is downregulated in human breast cancers and correlated with HER2 expression. Oncotarget. 6:12357–12368. 2015. View Article : Google Scholar : PubMed/NCBI
23	Fenaux P: Inhibitors of DNA methylation: Beyond myelodys-plastic syndromes. Nat Clin Pract Oncol. 2(Suppl 1): S36–S44. 2005. View Article : Google Scholar